Bristol-Myers Squibb Company (NYSE:BMY) is one of the top most undervalued low volatility stocks to buy now. On August 25, BMO Capital analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00.
The analyst supported the rating with the present performance and future expectations for Bristol-Myers Squibb Company’s product, Cobenfy.
Seigerman stated that the drug exhibited solid prescription growth, but the rate did not point to a considerable market breakthrough. The analyst expects the numbers to fall short of the consensus revenue expectations for fiscal Q3 2025 despite a rise in the weekly and monthly prescriptions.
Seigerman added that the revised assumptions regarding inventory levels and gross-to-net discounts add increased uncertainty to revenue forecasts, supporting the Hold rating.
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
